The clinical trial approval for the Group’s second generation of highly-effectiveabsorbed tetanus vaccine has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.

Tetanus is an extremely serious and potentially fatal disease, and tetanus vaccination is currently the most cost-effective and effective measure to prevent it. In addition, the Group is actively promoting the research and development of diphtheria, tetanus and acellular pertussis– HIB combined vaccine (the “Tetravaccine”), pentavalent vaccine and other multidiseasevaccine. Among them, the Tetravaccine is used to prevent invasive infections caused by pertussis, diphtheria, tetanus and Haemophilus Influenzae type b, and has the advantages of reducing the number of vaccinations for infants and young children, and enhancing the vaccination compliance of parents, infants and young children. The development of multidisease vaccine has become a trend in the industry. According to the data of China Insights Industry Consultancy Limited, an industry consultant, the Chinese market size of the multidisease vaccine is expected to reach RMB10 billion in 2030.

The research and development of the vaccine is in line with the Group’s strategic layout in product research and development and is an important step to realize the Group’s research and development of multidisease and multivalent products, which will further improve the Group’s product pipelines, help the Group enrich its product line and consolidate its industry position, and achieve sustainable and rapid growth in the Group’s performance.